Display options
Cite
Dwyer AR, Greenland EL, Pixley FJ. Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling. Cancers (Basel). 2017;9(6)doi: 10.3390/cancers9060068.
Dwyer, A. R., Greenland, E. L., & Pixley, F. J. (2017). Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling. Cancers, 9(6), . https://doi.org/10.3390/cancers9060068
Dwyer, Amy R, et al. "Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling." Cancers vol. 9,6 (2017). doi: https://doi.org/10.3390/cancers9060068
Dwyer AR, Greenland EL, Pixley FJ. Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling. Cancers (Basel). 2017 Jun 18;9(6). doi: 10.3390/cancers9060068. PMID: 28629162; PMCID: PMC5483887.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2017 Jun 18;9(6). doi: 10.3390/cancers9060068.

Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.

Cancers

Amy R Dwyer, Eloise L Greenland, Fiona J Pixley

Affiliations

  1. School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. [email protected].
  2. School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. [email protected].
  3. School of Biomedical Sciences, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. [email protected].

PMID: 28629162 PMCID: PMC5483887 DOI: 10.3390/cancers9060068

Abstract

Macrophages interact with cells in every organ to facilitate tissue development, function and repair. However, the close interaction between macrophages and parenchymal cells can be subverted in disease, particularly cancer. Motility is an essential capacity for macrophages to be able to carry out their various roles. In cancers, the macrophage's interstitial migratory ability is frequently co-opted by tumor cells to enable escape from the primary tumor and metastatic spread. Macrophage accumulation within and movement through a tumor is often stimulated by tumor cell production of the mononuclear phagocytic growth factor, colony-stimulating factor-1 (CSF-1). CSF-1 also regulates macrophage survival, proliferation and differentiation, and its many effects are transduced by its receptor, the CSF-1R, via phosphotyrosine motif-activated signals. Mutational analysis of CSF-1R signaling indicates that the major mediators of CSF-1-induced motility are phosphatidyl-inositol-3 kinase (PI3K) and one or more Src family kinase (SFK), which activate signals to adhesion, actin polymerization, polarization and, ultimately, migration and invasion in macrophages. The macrophage transcriptome, including that of the motility machinery, is very complex and highly responsive to the environment, with selective expression of proteins and splice variants rarely found in other cell types. Thus, their unique motility machinery can be specifically targeted to block macrophage migration, and thereby, inhibit tumor invasion and metastasis.

Keywords: Src family kinases; colony-stimulating factor-1; macrophage motility; paracrine interaction; phosphatidyl-inositol-3-kinase

Conflict of interest statement

The authors declare no conflict of interest.

References

  1. Oncoimmunology. 2013 Dec 1;2(12):e26968 - PubMed
  2. J Mammary Gland Biol Neoplasia. 2014 Jul;19(2):149-59 - PubMed
  3. J Cell Sci. 2008 Dec 15;121(Pt 24):4124-33 - PubMed
  4. J Cell Sci. 1989 Jul;93 ( Pt 3):447-56 - PubMed
  5. Nat Immunol. 2016 Jan;17(1):2-8 - PubMed
  6. J Leukoc Biol. 2016 Jul;100(1):163-75 - PubMed
  7. Development. 2003 Mar;130(5):817-33 - PubMed
  8. J Biol Chem. 2009 Aug 28;284(35):23302-11 - PubMed
  9. J Cell Sci. 2006 Jul 1;119(Pt 13):2749-57 - PubMed
  10. Science. 2008 May 9;320(5877):807-11 - PubMed
  11. J Mol Med (Berl). 2016 Jan;94(1):5-11 - PubMed
  12. Cell. 2013 Dec 19;155(7):1596-609 - PubMed
  13. Curr Opin Pharmacol. 2015 Aug;23:45-51 - PubMed
  14. Immunol Rev. 2014 Nov;262(1):25-35 - PubMed
  15. Cancer Sci. 2012 Nov;103(11):2012-20 - PubMed
  16. J Immunol. 2011 Oct 1;187(7):3806-14 - PubMed
  17. Mol Reprod Dev. 1997 Jan;46(1):4-10 - PubMed
  18. J Bone Miner Metab. 2013 Sep;31(5):486-95 - PubMed
  19. Semin Immunopathol. 2013 Sep;35(5):585-600 - PubMed
  20. J Biol Chem. 2007 Jun 29;282(26):18991-9 - PubMed
  21. Sci Transl Med. 2013 Apr 17;5(181):181ra52 - PubMed
  22. Ann Neurol. 2016 Oct;80(4):554-65 - PubMed
  23. Cancer Immunol Res. 2014 Aug;2(8):765-76 - PubMed
  24. J Cell Sci. 1997 Mar;110 ( Pt 6):707-20 - PubMed
  25. Trends Mol Med. 2011 Dec;17(12):743-52 - PubMed
  26. J Cell Sci. 2008 Mar 1;121(Pt 5):551-9 - PubMed
  27. Neurology. 2014 Jan 14;82(2):139-48 - PubMed
  28. J Exp Med. 2002 Sep 2;196(5):589-604 - PubMed
  29. Int J Dev Biol. 2011;55(7-9):861-7 - PubMed
  30. J Cell Sci. 1999 Nov;112 ( Pt 22):4067-78 - PubMed
  31. Mol Cell Proteomics. 2003 Nov;2(11):1143-55 - PubMed
  32. J Leukoc Biol. 2008 Sep;84(3):852-63 - PubMed
  33. Biochem Soc Trans. 2006 Nov;34(Pt 5):647-62 - PubMed
  34. Nat Med. 2013 Oct;19(10):1264-72 - PubMed
  35. Cancer Res. 2010 Jul 15;70(14):5728-39 - PubMed
  36. Immunity. 2014 Jul 17;41(1):49-61 - PubMed
  37. Nat Rev Clin Oncol. 2017 Jul;14 (7):399-416 - PubMed
  38. Nat Chem Biol. 2014 Apr;10(4):286-90 - PubMed
  39. J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):177-89 - PubMed
  40. Blood. 2003 Feb 1;101(3):1155-63 - PubMed
  41. Nat Immunol. 2016 Jan;17(1):9-17 - PubMed
  42. J Natl Cancer Inst. 1994 Jan 19;86(2):120-6 - PubMed
  43. J Immunol. 1988 Jul 15;141(2):575-9 - PubMed
  44. Trends Cancer. 2016 Oct 1;2(1):20-34 - PubMed
  45. Cancer Cell. 2014 Nov 10;26(5):623-37 - PubMed
  46. Cancer Res. 2013 Feb 1;73(3):1128-41 - PubMed
  47. N Engl J Med. 2014 Mar 13;370(11):1061-2 - PubMed
  48. Cancer Discov. 2011 Jun;1(1):54-67 - PubMed
  49. EMBO J. 1999 May 4;18(9):2459-71 - PubMed
  50. Nature. 1990 May 31;345(6274):442-4 - PubMed
  51. EMBO J. 1998 Aug 3;17(15):4391-403 - PubMed
  52. Oncologist. 2009 Jul;14(7):667-78 - PubMed
  53. EMBO J. 1992 Apr;11(4):1365-72 - PubMed
  54. Cancer Cell. 2014 Jun 16;25(6):846-59 - PubMed
  55. Annu Rev Cell Dev Biol. 1997;13:513-609 - PubMed
  56. Nat Rev Mol Cell Biol. 2010 Jan;11(1):9-22 - PubMed
  57. Nature. 2013 Apr 25;496(7446):445-55 - PubMed
  58. Nat Rev Immunol. 2009 Apr;9(4):259-70 - PubMed
  59. Cytoskeleton (Hoboken). 2014 Sep;71(9):542-54 - PubMed
  60. Neurol Sci. 2016 Sep;37(9):1565-9 - PubMed
  61. Int J Cell Biol. 2012;2012:501962 - PubMed
  62. Acta Neuropathol. 2014 Aug;128(2):191-213 - PubMed
  63. J Neuroinflammation. 2014 Feb 01;11:23 - PubMed
  64. Science. 2011 Jun 10;332(6035):1284-8 - PubMed
  65. Dev Dyn. 2006 Dec;235(12):3222-9 - PubMed
  66. Cancer Res. 2005 Jun 15;65(12):5278-83 - PubMed
  67. J Cell Biol. 1998 Jun 1;141(5):1147-57 - PubMed
  68. Immunity. 2014 Jul 17;41(1):14-20 - PubMed
  69. Neuro Oncol. 2016 Jun;18(6):797-806 - PubMed
  70. Oncogene. 2004 Oct 18;23(48):7906-9 - PubMed
  71. Mol Cell Biol. 2001 Mar;21(5):1795-809 - PubMed
  72. J Cell Sci. 2011 Jul 1;124(Pt 13):2120-31 - PubMed
  73. Cancer Res. 2004 Oct 1;64(19):7022-9 - PubMed
  74. Crit Rev Clin Lab Sci. 2012 Mar-Apr;49(2):49-61 - PubMed
  75. Blood. 2010 Aug 5;116(5):829-40 - PubMed
  76. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4828-32 - PubMed
  77. Front Biosci. 2008 May 01;13:4426-50 - PubMed
  78. Neurobiol Dis. 2015 Feb;74:219-28 - PubMed
  79. Cancer Cell. 2013 Mar 18;23(3):277-86 - PubMed
  80. Curr Opin Cell Biol. 2015 Oct;36:103-12 - PubMed
  81. J Leukoc Biol. 2010 Sep;88(3):495-505 - PubMed
  82. J Clin Invest. 1992 Oct;90(4):1622-7 - PubMed
  83. Science. 2017 Mar 24;355(6331):1317-1320 - PubMed
  84. Dev Biol. 2007 Aug 1;308(1):232-46 - PubMed
  85. J Biol Chem. 2002 Apr 26;277(17 ):14635-40 - PubMed
  86. Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17253-8 - PubMed
  87. J Biol Chem. 2012 Apr 20;287(17):13694-704 - PubMed
  88. Dev Biol. 2001 Oct 15;238(2):274-88 - PubMed
  89. Gynecol Oncol. 2014 Nov;135(2):176-83 - PubMed
  90. Nat Rev Immunol. 2011 Oct 14;11(11):723-37 - PubMed
  91. Development. 2000 Dec;127(24):5245-52 - PubMed
  92. Immunity. 2014 Jul 17;41(1):36-48 - PubMed
  93. Clin Lung Cancer. 2013 Nov;14 (6):666-673.e2 - PubMed
  94. Curr Rheumatol Rep. 2012 Oct;14(5):445-54 - PubMed
  95. Trends Immunol. 2004 Dec;25(12):677-86 - PubMed
  96. FEBS J. 2013 Nov;280(21):5228-36 - PubMed
  97. Trends Cell Biol. 2004 Nov;14(11):628-38 - PubMed
  98. Cell. 2011 Apr 29;145(3):341-55 - PubMed
  99. J Immunol. 2006 Nov 15;177(10):7303-11 - PubMed
  100. Nat Rev Immunol. 2008 Dec;8(12):958-69 - PubMed
  101. J Cell Sci. 2005 May 1;118(Pt 9):1873-83 - PubMed
  102. Cancer Cell. 2017 Apr 10;31(4):563-575.e5 - PubMed
  103. Nat Rev Immunol. 2003 Jan;3(1):23-35 - PubMed
  104. Cell. 2006 Jan 27;124(2):263-6 - PubMed
  105. Nat Genet. 2011 Dec 25;44(2):200-5 - PubMed
  106. Immunity. 2014 Feb 20;40(2):274-88 - PubMed
  107. J Cell Sci. 2011 Jun 15;124(Pt 12):2021-31 - PubMed
  108. Exp Hematol. 2000 Jun;28(6):601-11 - PubMed
  109. J Exp Med. 2001 Mar 19;193(6):727-40 - PubMed
  110. J Cell Sci. 1996 Apr;109 ( Pt 4):793-803 - PubMed
  111. Blood. 2002 Jan 1;99(1):111-20 - PubMed
  112. Nat Immunol. 2012 Jun 24;13(8):753-60 - PubMed
  113. Cancer Cell. 2012 Mar 20;21(3):309-22 - PubMed
  114. Oncol Lett. 2015 Sep;10(3):1390-1396 - PubMed

Publication Types